Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | STX-003 |
| Synonyms | |
| Therapy Description |
STX-003 is a self-replicating mRNA encoding IL-12 with programmable genetics to decrease expression in healthy tissues, which potentially induces antitumor immune response (Cancer Res (2025) 85 (8_Supplement_1): 3472). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| STX-003 | STX003|STX 003 | STX-003 is a self-replicating mRNA encoding IL-12 with programmable genetics to decrease expression in healthy tissues, which potentially induces antitumor immune response (Cancer Res (2025) 85 (8_Supplement_1): 3472). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07751042 | Phase Ib/II | Pembrolizumab + STX-003 STX-003 | Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Recruiting | USA | 0 |